Terms: = Leukemia AND HIST1H4I, MGC24116, 8294, P62805 AND Treatment
2 results:
1. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract] [Full Text] [Related]
2. Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration.
Delgado J; Ghita G; Baumann T; Santacruz R; Dlouhy I; Aymerich M; Rozman M; Creus N; Pereira A; Montserrat E
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):73-9. PubMed ID: 24126217
[TBL] [Abstract] [Full Text] [Related]
